| Reducing cardiac ischemic events in patients with ACS: prasugrel versus clopidogrel. Commentary. | |
| | |
MedLine Citation:
|
PMID: 20107305 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Prasugrel was associated with a statistically significant reduction in rates of cardiac ischemic events in patients with ACS who had undergone PCI. Rates of post-PCI death from cardiovascular causes, nonfatal MI, or nonfatal stroke were also significantly reduced with the use of prasugrel versus clopidogrel. Major bleeding was significantly increased with the use of prasugrel versus clopidogrel. Mortality did not differ significantly between the groups. |
| | |
Authors:
|
Scott Solomon; James L Vacek |
Related Documents
:
|
18388505 - Major clinical vascular events and aspirin-resistance status as determined by the pfa-1... 2382605 - Unstable angina or non-q wave infarction despite long-term aspirin: response to thrombo... 18081375 - Parnaparin : a review of its use in the management of venous thromboembolism, chronic v... 9727545 - Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a d... 10335875 - Plasma lipids, lipoproteins and apolipoproteins and sudden cardiac death. 19131865 - Near infrared spectroscopy changes with pericardial tamponade. |
Publication Detail:
|
Type: Clinical Trial, Phase III; Comment; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Postgraduate medicine Volume: 122 ISSN: 1941-9260 ISO Abbreviation: Postgrad Med Publication Date: 2010 Jan |
Date Detail:
|
Created Date: 2010-01-28 Completed Date: 2010-02-25 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0401147 Medline TA: Postgrad Med Country: United States |
Other Details:
|
Languages: eng Pagination: 198-200 Citation Subset: AIM; IM |
Affiliation:
|
The University of Kansas Medical Center and Hospital, 39th and Rainbow Blvd., Kansas City, KS 66106, USA. csolomon@kumc.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Coronary Syndrome
/
complications*,
drug therapy Aspirin / therapeutic use Confidence Intervals Double-Blind Method Drug Therapy, Combination Humans Myocardial Ischemia / drug therapy, etiology, prevention & control* Piperazines / therapeutic use* Platelet Aggregation Inhibitors / therapeutic use Pyridines / therapeutic use Thiophenes / therapeutic use* Ticlopidine / analogs & derivatives*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Piperazines; 0/Platelet Aggregation Inhibitors; 0/Pyridines; 0/Thiophenes; 0/prasugrel; 0/thienopyridine; 50-78-2/Aspirin; 55142-85-3/Ticlopidine; 90055-48-4/clopidogrel |
| Comments/Corrections | |
Comment On:
|
N Engl J Med. 2007 Nov 15;357(20):2001-15
[PMID:
17982182
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Patient self-treatment using lansoprazole for frequent nighttime heartburn. Commentary.
Next Document: Comparing insulins detemir and glargine in type 2 diabetes: more similarities than differences. Comm...